We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.275 | -3.18% | 8.375 | 8.25 | 8.50 | 8.375 | 8.375 | 8.375 | 20,060 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIXI
RNS Number : 3797W
IXICO plc
09 February 2017
9 February 2017
IXICO plc
("IXICO" or the "Company")
Share option grant to Directors
IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that on 7 February 2017 the Remuneration Committee agreed to grant options to the Company's Executive Directors and employees in accordance with the rules of the Company's EMI Share Option Plan 2014(the 'Plan') exercisable at a price of 36.5p.
The award of options under the Plan are over the ordinary shares in the Company and are subject to performance conditions. The options will vest upon the achievement of strategic corporate goals in respect of commercialisation of the Company's products and/or services or a significant corporate development transaction within three years of the date of grant.
The total number of options being issued at this time is 1,044,698. The following table sets out the details of the options that have been granted to the Executive Directors:
Name of Director Number of Total number Percentage of options of options held issued share granted capital under option ------------------ ---------- ----------------- --------------- Giulio Cerroni 676,582 676,582 2.5% ------------------ ---------- ----------------- --------------- Derek Hill 80,000 540,236 2.0% ------------------ ---------- ----------------- --------------- Susan Lowther 80,000 490,196 1.8% ------------------ ---------- ----------------- ---------------
For further information please contact:
IXICO plc Charles Spicer, Non-Executive Chairman Tel: +44 20 3763 Susan Lowther, Chief Financial Officer 7499 and Company Secretary Shore Capital (Nomad and Broker) Tel: +44 20 Bidhi Bhoma / Edward Mansfield 7408 4090 FTI Consulting Limited (Investor Tel: +44 20 Relations) 3727 1000 Simon Conway/Mo Noonan/Matthew Moss
About IXICO
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUWANRBVAURAR
(END) Dow Jones Newswires
February 09, 2017 02:00 ET (07:00 GMT)
1 Year Ixico Chart |
1 Month Ixico Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions